Progress with a difficult infection

The Lancet Infectious Diseases

Volumn 12, Issue 4, 2012, Pages 256-257

  Wilcox, Mark H ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; DIARRHEA; DRUG COST; DRUG TREATMENT FAILURE; HOSPITAL ADMISSION; HUMAN; INFECTION RISK; LETTER; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT DURATION;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; MALE; VANCOMYCIN;

EID: 84859005915     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70013-0     Document Type: Letter

References (13)

1. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile infection in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised, controlled trial. Lancet Infect Dis 2012, for the OPT-80-004 Clinical Study Group, published online Feb 8. 10.1016/S1473-3099(11)70374-7.
2. Rupnik M, Wilcox MH, Gerding DN Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009, 7:526-536.
3. Wilcox MH, Spencer RC Clostridium difficile infection: responses, relapses and re-infections. J Hosp Infect 1992, 22:85-92.
4. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011, 364:422-431. for the OPT-80-003 Clinical Study Group.
5. Tvede M, Rask-Madsen J Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989, 333:1156-1160.
6. Tannock GW, Munro K, Taylor C, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010, 156:3354-3359.
7. Gough E, Shaikh H, Manges AR Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011, 53:994-1002.
8. Bauer MP, Kuijper EJ, van Dissel JT European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009, 15:1067-1079. for the European Society of Clinical Microbiology and Infectious Diseases.
9. Hu MY, Katchar K, Kyne L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 2009, 136:1206-1214.
10. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011, 53:440-447.
11. Eyre DW, Wyllie D, Dingle KE et al. Predictors of recurrent Clostridium difficile infection: Implications for initial management. 49th Conference of Infectious Diseases Society of America; Boston, MA, USA; Oct 20-23, 2011. 352.
12. Eyre DW, Walker AS, Griffiths D, et al. Clostridium difficile mixed infection and reinfection. J Clin Microbiol 2012, 50:142-144.
13. Goldstein EJ, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother 2011, 55:5194-5199.